Advances in Consumer Research
ISSN (Print): 0098-9258
ISSN(Online): 3079-1766

Vol. 2, Issue 2 (2025) https://acr-journal.com/

The Role of Psychedelics in Entrepreneurial Creativity and Mental Well-Being

Suraj Kumar[1], Akhil Goyal[2*]

[1]Research Scholar, Nims School of Business, Nims University Rajasthan, Jaipur
[2]Associate professor, Nims School of Business, Nims University Rajasthan, Jaipur
Email ID: Suraj.kumar@nimsuniversity.org
Email ID: Akhil.goyal@nimsuniversity.org

Cite this paper as: Suraj Kumar, Akhil Goyal, (2025) The Role of Psychedelics in Entrepreneurial Creativity and Mental Well-Being. *Advances in Consumer Research*, 2 (2), 831-841.

KEYWORDS
Psychedelics, Entrepreneurship, Creativity, Mental Well-being, Innovation

ABSTRACT
Despite very little known about their potential influence on leadership outcomes and its implications in leadership behaviour, psychedelic drugs and mindfulness meditation are promising as mental health therapies. The aim of this research was to ascertain if and how the use of psychedelic and mindfulness meditation affects leadership of respondents whose primary job was management. Although causation cannot be deduced by the research methodology, the results of this study suggest possible complimentary benefits of mindfulness meditation and psychedelic usage on leadership which may lead to new techniques in leadership development.:

1. INTRODUCTION

1.1 Definition of Psychedelics

'Entrepreneurial intention' (EI) is explicated as "mental orientation (desire, wish and hope) inducing their selection of entrepreneurship" (Guerrero et al., 2008; Wu and Wu, 2012). Entrepreneurial self efficacy (ESE) is defined as one's confidence in being able to start up an any business and achieving the start up advancement (Chen et al. 1998; Segal et al. 2005). Tsai et al. (2016) also extended the relationship from ESE to EI by testing if the perceived entrepreneurial control and attitudes towards entrepreneurship mediate the relationship.

To the effect of subjective norms as a moderator of (ATE). Other such variables associated with entrepreneurship should also be studied to see whether interesting results came out, they said. Clearly, several factors, such as personal attributes, traits, background, experience and keeping disposition, can stimulate an individual's intention to become an entrepreneur. Based on previous research, In the context of entrepreneurship (Ardichvili et al., 2003), identifying an "opportunity" in the business sector is the basic step of the entrepreneurial process and exploiting the perfect opportunities for innovative business represent the substantial talents and skills of an effective businessperson. The authors in this study, claim that entrepreneurs with novel ideas, who leverage market opportunities to make PROFIT are easily able to take advantage of the market. These novel and original concepts refer to the creativity, and in the context of entrepreneurship, it is called "entrepreneurial creativity" (EC). In 1997, Amabile defined EC as the new venture launch, found out from unique, distinctive and accurate ideas. Amabile (1997) claimed that EC is necessary under the assumption of the impeded transactions in the entrepreneurial process. This study states that if applied, local and novel ideas (EC), will see the growth of the ESE and increase their intentions to be entrepreneurs. In the mode of such, after which, according to Ajzen (1991), 'theory of planned behaviour' (TPB), also the personal belief that the individual has the capacity or capacity to carry out certain behaviours affects the attitudes towards such a behaviour and the individuals' appetite or thirst for unique and interesting ideas and this then arouses the intention of performing a behaviour like such. Literally translated this theory tell us that this theory suggests interaction between EC (for thirst of new ideas) and ATE (as elaborated by Tsai et al., 2016) in the chain of linkage between 'ESE and EI'.

1.2 Brief History and Cultural Context

Understanding the underlying mechanisms of the effects of so-called "psychedelic" or "hallucinogenic" substances under experimental conditions has historically posed a significant challenge, as these substances are highly influenced by cultural

context [9]. Timothy Leary introduced the terms “set” and “setting” to describe the extra pharmacological factors shaping drug experiences, while Claude Lévi-Strauss suggested that hallucinogens act as “triggers and amplifiers” of an inherent cultural discourse, facilitating its articulation [10].

Moreover, as indicated previous studies (Lee et al., 2005), people who receive higher educational entrepreneur, are more prone to pursue innovative business opportunities as a career. Identifying business men from non-business men is an important factor of educating the people about entrepreneurship. Previous studies have attempted to study the direct effect of EE on the EI (Ahmed et al., 2017; Lee et al., 2005; Lorz and Volery, 2011). In addition, it is worth mentioning that the EE moderates the relationship between ESE and EI in a few studies (Piperopoulos and Dimov, 2015; Wilson et al., 2007). For instance, the moderating effect of EE on the mediated relationships between ESE and EI mediated by ECE as well as ESE and EI attitudes to entrepreneurship are investigated in this study, by extending the previous research. It is argued in this study that individuals with the Essentialise and corresponding high ESE will also achieve high self-belief. Accordingly, it would lead to a change in EI which is positive, with the impactful change on EE being accommodating ESEEI (Piperopoulos and Dimov 2015; Wilson et al. 2007). In Cho's (1998) study, it was also stated that the importance of EE is from the fact that it motivates people to develop a business based on inspiration received through knowledge and skills, e.g., entrepreneurship. By suggesting that human beings can be able to conceive of the creative ideas that help in the establishment of new ventures apart from the knowledge of essential entrepreneurship.

Psychedelic substances were almost exclusively linked to countercultural movements until recent years because they faced popular stigmatization through their classifications under legal statutes and their utilization as recreational drugs. Research conducted recently have exposed psychedelic drugs as possible treatments for mental health disorders. The new research results about psychedelics bring about a major strategic turn of international business operations for the global wellness sector. In an inspiring and at the same time complicated field of research, psychedelics and wellness work together. Immediate analysis of tight links between wellness and psychedelic industries and their complex worldwide business effects is required, since the global understanding has changed. Traditional use of psilocybin and LSD, as well as South American aquatic plants, by many of their indigenous traditions in sacred and restorative ways have persisted. Their development has been very controversial in modern times. Regulations were then passed by governments to regulate their use, though recreational use of these substances increased in the 1960s. Thousands of years various cultures have already had psychedelics namely drug varieties for their religious and extra psychological and cultural needs. These substances have always been integrated into the life of humanity since the beginning of history. Recreational and therapeutic uses. This section delves deeper into their tumultuous journey from ancient rituals to modern controversies.

Historical Use: Psychedelic compounds such as psilocybin mushrooms, peyote, and ayahuasca have been used for requirements of a number of 1000’s of years. Ayahuasca, a brew also made with The *Banisteriopsis caapi* vine plants other, is used for spiritual and healing ceremonies by indigenous tribes in regions ranging from the Amazon Basin. Pevey pot also played a role amongst Native American tribes as it is regarded as spiritual and Psilocybin mushrooms too were sacred to a number of regions from Central America and old Saharan tribes.

Researchers and now, more so than ever, countercultural figures, rediscovered and explored these substances in the 20th century. Orne went on to use psychedelics in the 1950s and 1960s, such as LSD, advocating for them as consciousness expanding and in the psychological therapy field, figures such as Aldous Huxley and Timothy Leary.

The Controversial 1960s: The late 1960s were pivotal. With psychedelics’ use becoming tied to counterculture movement, however, their recreational use became widespread. These substances were linked with anti-establishment sentiments and were stigmatized by a crackdown.

In the course of the 1960s, many countries passed laws criminalizing the use and possession of many psychedelics due to the imposition of the position by several international conventions, including the United Nations' 1971 convention on Psychotropic Substances.

Strict regulations: Since the 1960s, any research about possible benefits psychedelics had hit a brick wall. Most of the substances were mainly classified into Schedule I drugs with high potential of abuse and no accepted medicinal use countries. Fortunately, the 21st century saw a renaissance of psychedelic research, 21st Century Renaissance: when neuroimaging and a popularity of psychotherapy brought psychedelics back to Johns Hopkins University and Imperial College London. They were modelling to change the global perception with their results demonstrating novel potential for therapy. Map’s data, published in 2021, reveals that to date more than 60 clinical trials of psychedelics’ potential for therapeutic use are underway in the world. Nonetheless, psilocybin assistance therapy has made it to phase III trials for the treatment resistant depression and therefore holds some promise as a pathway to medical legalization.

Modern Controversies and Debates: The modern psychedelic journey both celebrates and complicates these ethics (although the line between celebration and complication and the extent to which they overlap may be blurred), as well as the fact of the hype, buzz, and buzzkill associated with the commercialization of substances directly derived from indigenous practices, because of potential misuse in recreational contexts and fears about how rapid for-profit motives can become in a nascent industry.

2. THE RESURGENCE OF PSYCHEDELICS

In the 21st Century, scientific research has begun to prove that psychedelics can help with depression, anxiety, PTSD and addiction. Ground-breaking studies have been published by institutions like Johns Hopkins University and Imperial College London and that have changed perceptions on these substances. And it is in the 21st century that the current narrative around psychedelics took a dramatic turn. Recent clinical trials of these substances have reawakened the interest of scientific and clinical communities which were once abandoned in favour of treatments that did not meet the same unmet medical need in mental health treatments.

Psychedelics act on the brain by targeting its serotonin receptors, which are the main targets of the brain. Classic psychedelics like LSD, psilocybin and DMT are known to interact with the 5HT2A receptor subtype in order to change mood, perception and cognition. One of the effects that modern methods of neuroimaging have shown is that these substances increase the level of connectivity among various parts of the brain, which can help to break rigid thought patterns in disorders such as depression.

2.2 Types of Psychedelics (e.g., LSD, Psilocybin, DMT, MDMA)

The Swiss chemist Albert Hofmann did not synthesize the first chemical hallucinogen (lysergic acid diethylamide, or LSD) until 1938, during which time he was working with the pharmaceutical company, Sandoz (1, 2). In the course of a series of experiments on April 16, 1943, Hofmann encountered the LSD accidentally, and an “uninterrupted stream of fantastic pictures, extraordinary shapes with intense, kaleidoscopic play of colours” (1) resulted. Already by 1947, Sandoz now supplied LSD to psychologists, psychotherapists and psychiatrists not so much in accordance with psychotherapeutic practice but as adjunctive therapy medicine or for the psychological experimental study of the nature of psychoses — thus Ceská Směna [Flow] is written belonging to the trade name Delysid (1).

In 1960, Timothy Leary started experiments with the Harvard Psilocybin Project to know whether or not psilocybin could be utilised as an adjunct to psychotherapy. In 1963, one of the other of his Harvard colleagues, Richard Alpert, dismissed him alongside Harvard as well, and, according to Leary, he tried LSD. LSD began to be used in the vast number of medically unsupervised settings, and the last of the Sandoz patents for the production of LSD expired in 1963, after which illicit production of LSD increased (1). By 1965, governments in the European and American states became alarmed as countries began to figure out that psilocybin is being massed in Sweden, Holland and the United States. Drug Abuse Control Amendments passed by U.S. Congress made selling and producing LSD a misdemeanor, and banned all researches without FDA’s Investigational New Drug exemption from U.S. Food and Drug Administration (FDA) from obtaining their supplies of LSD (1). The Controlled Substances Act, as a part of the Comprehensive Drug Abuse Prevention and Control Act of 1970 banned clinical experiment and research with psychedelics altogether, and did both. Thirty years later, Paul Grondahl, the reporter who wrote those lyrics beginning, 'But that psychedelic research is dead,' by Ray Thomas of the Moody Blues, and for which Timothy Leary died in 1996, was prescient as to the Controlled Substances Act. Just a year later, in 1971, President Richard Nixon declared the ‘War on Drugs’, and much experimentation in psychedelics became hidden, underground, with the psychedelic experimentation spreading around the United States and across Europe, falling out with the countercultural movements.

Over the past decade interest in the therapeutic potential of psychedelic compounds has surged and this number of review articles and clinical trials reports has held relatively constant. In the United Kingdom, there are several groups which have contributed to research on these compounds including the members of United Kingdom Medical Research Council a nationally funded health agency and Multidisciplinary Association for Psychedelic Studies (MAPS), a nonprofit association set up in 1986 to enhance the knowledge base of psychedelic substances. Support has also been added by the Heffter Research Institute, a 1993 non-profit, non-governmental, scientific organization committing itself to funding the work with the classic hallucinogens and related compounds while the Beckley Foundation, a research and nongovernmental organization in the United Kingdom, also dedicated to promoting psychedelic research, drug policy reform. Most of these organisations also use most of the pivotal trials, and they work with regulatory agencies such as FDA, European Medicines Agency to ensure these studies are in concordance with guidelines which the studies followed before the approval for clinical use. Modern psychedelic drug research has been conducted by leading academic research universities around the world such as Johns Hopkins University, University of California, Los Angeles, New York University, Imperial College London, University of Zurich, University of Basel. Both Johns Hopkins University and Imperial College London have recently opened psychedelic research centres that attempt to understand what psychedelic drugs do to the mind and brain to alter psychiatric disorders.

Table 1: Psychedelics and Creativity in Entrepreneurs

Aspect	Description	Impact on Entrepreneurs	References
Enhanced Divergent Thinking	Psychedelics promote **non-linear thinking**, boosting **idea generation** and creative flexibility.	Entrepreneurs experience **novel solutions** and unconventional problem-solving.	[38, 39]

Improved Problem-Solving	Psychedelics **disrupt habitual thinking patterns**, enabling fresh approaches to complex issues.	Supports **innovation** and strategic decision-making.	[40]
Case Studies of Usage	Entrepreneurs have reported **microdosing** for enhanced **creativity and focus**.	Improved **product development** and creative brainstorming sessions.	[41, 42]
Impact on Innovation	Psychedelics enhance **cognitive flexibility**, fostering new business concepts and product designs.	Increased **innovation** and exploration of unique business models.	[43]
Risk-Taking Behavior	Moderate psychedelic use **reduces fear of failure**, promoting **calculated risk-taking**.	Entrepreneurs display greater **boldness** in business ventures.	[44]
Neuroplasticity	Psychedelics stimulate **neuroplasticity**, fostering adaptive learning and creativity.	Enhanced **creative adaptability** and resilience.	[45]
Cognitive Flexibility	Promotes **open-mindedness** and flexible thinking by altering brain connectivity patterns.	Entrepreneurs explore **diverse strategies** and pivot more effectively.	[46]

3. ENHANCING CONSCIOUSNESS AND COGNITION THROUGH MICRODOSING PSYCHEDELICS

Since the 1990s, the Psychedelic Studies (PS) movement has become increasingly visible and popular within academia as well as outside it, due to substantial investment in neuroscience research and gradual progress in drug policy reforms in countries such as the US and Switzerland. The movement wants to detach hallucinogens from a taint of association with the 1960s counterculture and embed them in brain research in order to gain institutional legitimacy. 'Not only would this field allow scientists to study the effect of LSD on mood optimization and cognition and creativity, but, in fact, the hallucinogenic effects of LSD have left people curious about a natural way to access the creative aspects of consciousness,' say neuroscientists. The use of psychedelics by healthy individuals is thought by proponents as a part of human evolutionary psychology.

In particular, microdosing is touted as a combination of the mainstream business and psychedelic values, and they're being used by business entrepreneurs, who are easy to recruit. While no scientific studies assess the effects of microdoses of psychedelics on healthy people, the practice has suddenly become the subject of interest by American and European media since about 2010. The second, it has been widely reported in online reports of personal experience and major data collections from Internet forums. There are psychedelic researchers who have published literature reviews on the topic or partially replicated the 1966 study by Harman to investigate whether creativity enhancement or psychosis-like effects is enhanced by psychedelics.

3.1 Fieldwork Encounters

During fieldwork, the researcher met various individuals connected to the psychedelic community, including:

- A biochemistry student participating in Fadiman's data collection on microdosing.
- A long-term meditator with ties to the Heffter Research Institute, which studies psychedelics.
- A member of the French Psychedelic Society (FPS).
- Paul Austin, the founder of The Third Wave (TTW), and another TTW member.
- The son of psychologist Timothy Leary, a pioneer in psychedelic research.

Three neuropsychopharmacology and psychiatry researchers studying the effects of psychedelics on creativity and psychosis.

A spokesman for the Foundation for Shamanistic Studies (FSS), founded in 1979 by anthropologist Michael Harner, devoted to providing shamanic knowledge in order to heal and save the earth.

These meetings were made possible by connecting with people during the researcher's master thesis on the revival of psychedelic assisted psychotherapy in Switzerland in the 2000s and by being part of the attending of the PS conferences in Prague, Berlin and German speaking Switzerland from 2015 to 2017.

3.2 Shifts in Attention and Intention

When asked about their microdosing practices, enthusiasts described it as being akin to a "bad day's cup of coffee" or simply a way to have a "normal yet really good day" (Austin). They believed that the best time to start a microdosing regimen was during periods without major life pressures. A typical microdosing day involved:

- Taking LSD, psilocybin, or ayahuasca upon waking.
- Engaging in meditation, yoga, or gym workouts to establish a positive mindset.
- Using the experience to gain mental clarity on daily goals and personal intentions.
- Microdosing was primarily perceived as a tool for enhancing mindfulness. Participants reported:
- Feeling more present in the moment, with reduced rumination about the past or future.
- Improved engagement and interaction with others.
- Increased intuition and clarity of hunches, impressions, and subconscious thoughts, making it easier to trust their instincts in daily life.

As one FPS member expressed:

"It made more present the things that were already here—hunches, intuitions, and impressions that are often hard to identify amid the rush of everyday life."

3.3 Neuro-Psychedelic Leadership: Microdosing as a Tool for Business Optimization

Lately, there has been anecdotal evidence of people using altered states of consciousness to boost leadership and achieve the best (Kotler and Wheal, 2017). There are many ways of attaining altered states of consciousness; two that have become well known through society are mindfulness meditation and psychedelic like lysergic acid diethylamide (LSD) (Simonsson et al., 2020; Livne et al., 2022). But there is little evidence from the empirical side of the effects of such interventions including psychedelics on the emergence of leadership.

Research has found that developing mindfulness meditation or other practices have similar effects on a number of leadership related outcomes (Donald et al., 2021). Urrila's (2021) systematic review of mindful leadership demonstrates its broad potential as a training intervention supporting leadership development, locating 28 leadership related outcomes (including stress reduction, sleep, creativity, and emotion regulation) as potentially affected by mindfulness-based interventions. To date, however, prior studies on mindful leadership have not measured the construct on nationally representative samples without large amounts of self-selection bias as well as very small samples. Mindfulness research on possible negative consequences of mindfulness training for leadership remains wanting (for a list of negative consequences of meditation see Britton et al., 2021; see also Purser, 2018). Thus, to do better than what has been found before, it is necessary to solve these constraints.

Although there is limited research on psychedelics in leadership literature, recent quantitative results also show that psychedelics can also influence leadership related outcomes such as psychological health (Galvão-Coelho et al., 2021), cognitive execution of the thoughts (Prochazkova et al., 2018; Wießner et al., 2022), and interpersonal values and behaviors (Griffiths et al., 2006, 2008; Roseman et al., 2021) if administered in harmless and helpful environments. According to earlier qualitative studies, frequent low-dose psychedelic use over extended periods of time (also known as "microdosing") may affect leadership-related outcomes and productivity (Webb et al., 2019; see also Johnstad, 2018; Fadiman and Korb, 2019; Hutten et al., 2019). There is nothing known about the direct relationship between psychedelics use and leadership outcome, but it is possible that psychedelics may be considered as potential leadership development aid.

As has been previously studied, the phenomenology and neurophysiology of such psychedelic induced altered states could convey similarities to that of mindfulness meditation (Millière et al., 2018). Other studies support that psychedelic use and mindfulness meditation may have complimentary long-term benefits, in principle they may be combined to enhance and expand positive effects (Heuschkel and Kuypers, 2020). Nevertheless, they have not investigated whether the effects psychedelic usage and mindfulness meditation are likely to be via processes of leadership development could be similar or different.

The aim of the current research was to contribute that gap in the literature examining; the perception of how psychedelic experiences, or mindfulness meditation leads to leadership in the workplace. In order to examine, at both quantitative and qualitative levels, whether and how mindfulness meditation and psychedelic use impact leadership in individuals in the upper management role at work, who are male, aged 25 years and over, and who were either UK or US adult representative populations by sex and ethnicity (n = 9,732). Finally, psychedelic is used and the efficacy of mindfulness meditation are also examined in order to further understand how such self-reported effects may mix and differ from one another.

These results cannot be interpreted on the basis of the study design though. Even if two researchers coded the replies independently, the opportunity remains that respondents or other researchers will contest the coding. It could have also been beneficial to now more than two researchers to code the replies to try to lessen any possible bias. Secondly, the respondents were only let ask one qualitative question about their leadership in addition they were not asked other information, which would be necessary in evaluation if they were using psychedelics or mindfulness meditation like age they first used them, context they use them, way they were taught mindfulness and quantity of psychedelics. For example, if the inquiry was about whether mindfulness meditation or psychedelics usage came before job experience in a managerial role, for example, it would have been useful to be better able to understand temporal sequence. Additionally, the duration of the possible

impacts (e.g., temporary, persistent) was not addressed in the single qualitative question. Third, those who indicated that they were now employed were asked to choose the answer that best reflected their main job function; no further questions that would have been helpful were asked (e.g., firm size, staff duties). Fourth, because of the study's cross-sectional methodology, the results cannot be used to infer causation. Fifth, there is a greater chance of answer biases since the replies were self-reported and retrospective, and they were gathered from a single survey (Podsakoff et al., 2003). For example, reactions pertaining to drug usage (Latkin et al., 2017) may have been impacted by social desirability (Van de Mortel, 2008). Sixth, while the samples were stratified by sex, age, and ethnicity to match the US and UK populations, it's likely that people who have had bad experiences with psychedelic use or mindfulness meditation are underrepresented on online job boards like Prolific Academic. The results' capacity to be applied broadly would be restricted if this were the case. To further understand if, for whom, and under what conditions mindfulness meditation and psychedelic use could affect leadership development, future research should make use of longitudinal study approaches, including randomized controlled trials, and in-depth qualitative interviews. Examining the possible negative impacts of psychedelic usage and mindfulness meditation would be very crucial, especially in light of the workplace.

3.4 Microdosing as a Pragmatic Tool

Austin framed microdosing psychedelics as a practical, value-free technique for enhancing creativity, well-being, and professional success. By altering brain patterns, microdosing was portrayed as a cognitive technology capable of fostering out-of-the-box thinking and promoting a more sustainable and fulfilling business environment Figure 1.



Figure 1 this image shows how, with eyes-closed, much more of the brain contributes to the visual experience under LSD than under placebo. The magnitude of this effect correlated with participant's reports of complex, dreamlike visions

4. SCIENTIFIC EVIDENCE AND RESEARCH STUDIES

Schlag et al. [51] investigate the possible negative effects of traditional psychedelic substances in their 2022 narrative review, seeking to distinguish between anecdotal accounts and methodical, evidence-based studies. Stigma and misunderstandings continue to cloud public and political attitudes of psychedelics, despite mounting scientific evidence of their therapeutic effectiveness in treating a range of medical ailments. The assessment has a comprehensive viewpoint, including physiological effects like toxicity and overdose as well as psychological and psychiatric dangers like dependency, abuse potential, and mental health issues. The authors emphasize that when psychedelics are administered in controlled, therapeutic settings, the dangers to health are often negligible. Furthermore, the majority of detrimental psychological impacts occur in uncontrolled or recreational situations rather than in therapeutic settings, and many of the negative consequences often mentioned in public discourse are not substantiated by existing scientific research. The study emphasizes that while employing psychedelics in medical settings, doctors and therapists must adhere to strict safety and ethical guidelines. The authors warn against sensationalized media coverage or aggressive marketing, since these might rekindle debates and impede future studies. The study concludes by highlighting the significance of truthful, evidence-based communication in promoting educated public debate and assisting with the ongoing investigation of the therapeutic potential of psychedelics [51].

Siegel et al. [52] examine the expanding corpus of clinical research on psychedelics for the treatment of mental diseases in their 2021 study that was published in the Journal of mental Research. A family of hallucinogenic medications known as psychedelics has shown encouraging promise in the treatment of mental health disorders by inducing unusual states of consciousness. The authors identified 70 ongoing or completed trials examining the therapeutic use of psychedelics (apart from ketamine) using a systematic review of clinical studies listed on clinicaltrials.gov as of December 3, 2020.

Methylenedioxymethamphetamine (MDMA) (45.7%) and psilocybin (41.4%) were the subjects of most of these trials, whereas ayahuasca (1.4%), lysergic acid diethylamide (4.2%), ibogaine hydrochloride (2.8%), salvia divinorum (1.4%), 5-MeO-DMT (1.4%), and DMT fumarate (1.4%) were the subjects of fewer studies. The majority of research on MDMA, psilocybin, ayahuasca, and salvia divinorum examined how well they worked to treat major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). Ibogaine hydrochloride, on the other hand, was investigated for drug and alcohol use disorders, while LSD was mostly investigated for major depressive disorder, anxiety, and severe somatic disorders. DMT fumarate and 5-MeO-DMT were evaluated for MDD. The bulk of the 70 research are still continuing or unfinished, and just 21 of them have published findings, the authors point out. The authors stress the significance of prioritizing future research based on the most relevant and positive results, urging researchers and stakeholders to concentrate on regions with the highest therapeutic promise in light of the growing number of psychedelic studies. [52]

5. LEGAL AND ETHICAL CONSIDERATIONS

Research on psychedelic therapies shows some promise, namely for use in treating psychiatric disorders such as depression with psilocybin and trauma with 3,4-methylenedioxymethamphetamine (MDMA). Carhart-Harris et al. (2021), COMPASS Pathways (2021) and Davis et al. (2022) all consider psilocybin to be effective for MDD; Mitchell et al. (2021) also discuss an MDMA assisted therapy for PTSD. In addition, more research is being conducted to determine the therapeutic effects of psychedelics on other mental health conditions. Yet, at this point, the available evidence is still limited, as small sample sizes are common for published evidence compared to Phase 3 trials on conventional antidepressants. Furthermore, studies often involve highly selective and possibly atypical participants, and many findings still require replication for broader validation. Despite these limitations, the promising results and the growing movement toward the legalization or decriminalization of psychedelics in certain regions raise significant ethical and policy considerations. Research by the authors identifies four distinct domains of ethical problems with emphasis on psilocybin as the psychedelic substance that displays the most promising therapeutic applications. The analysis applies to traditional psychedelic substances including MDMA in addition to similar psychoactive chemical compounds.

Table 2: Novel Ethical and Regulatory Challenges for Psychedelics

Challenge	Description	Key Considerations	References
Informed Consent and Vulnerability	Ensuring participants understand the **psychedelic experience**, including potential **risks**, unpredictable effects, and emotional sensitivity.	Special protections for **vulnerable groups** (e.g., trauma survivors).	[53]
Psychological Safety and Support	Need for **trained therapists** and proper **psychological support** during and after sessions to manage challenging experiences.	Implementing **integration therapy** for long-term well-being.	[54]
Risk of Adverse Reactions	Potential for **psychotic episodes**, anxiety, or emotional distress in some individuals, especially those with **psychiatric vulnerabilities**.	Pre-screening for **psychological stability**.	[55]
Accessibility and Equity	Risk of **inequitable access** due to high costs of therapy, limiting benefits to wealthier individuals.	Ensuring **affordable access** and insurance coverage.	[56]
Medicalization vs. Decriminalization	Debate over whether psychedelics should remain in **regulated medical settings** or be legalized/decriminalized for broader public use.	Balancing **therapeutic regulation** with individual freedom.	[57]
Long-Term Efficacy and Safety	Need for **long-term studies** on efficacy, safety, and potential **neurobiological changes** caused by repeated psychedelic use.	Ongoing **clinical trials** and pharmacovigilance.	[58]
Commercialization and Exploitation	Concerns about **corporate interests**, patents, and profit-driven motives affecting **patient care** and access.	Promoting **ethical business practices** and affordable pricing.	[59]
Cultural	Use of **traditional Indigenous practices**	Respect for **Indigenous**	[60]

Appropriation	(e.g., ayahuasca ceremonies) in Western contexts without cultural sensitivity or respect.	**knowledge** and equitable benefit-sharing.	
Legal and Policy Uncertainty	Inconsistent **regulations** across regions regarding psychedelic use, legality, and research approval.	Advocating for **standardized global policies** and ethical oversight.	[61]

6. PRACTICAL CONSIDERATIONS FOR ENTREPRENEURS

Most areas remain very strict to handle psychedelic drug restrictions, which means those who launch psychedelic businesses will need to deal with the extremely strict regulatory systems. The psychedelic industry's businesses must keep up to date with changing laws at local and national levels for fear of very serious risks if they do not comply. Another essential step is to obtain permits of licenses, and they mostly benefit industries which conduct clinical trials and develop psychedelic drugs and assisted therapy. Patenting new drug formulations along with delivery systems and treatment approaches will protect entrepreneurs from competitors in the market, which are important for them to stay ahead of the competition. Scientific research and clinical trials are required to verify the safety and effectiveness of psychedelic products in order to validate them. Start-ups cooperate with university research institutions to increase legitimacy and to get required regulatory approvals.

Nevertheless, this treatment needs patients to be psychologically vulnerable, and thus safety and ethical precautions still crucial. To maintain safety, caring entrepreneurs must set up standard protocols of comprehensive safety starting with consent and monitoring of healthcare providers and post treatment assistance to protect participant safety and build trust in patients. For the success of any psychedelics business, it is important to establish a solid business structure which can support the business operations, no matter which field the psychedelics business operates in – from production of drugs all the way to therapy solutions and mental healthcare. Due to increasing financial value of the industry, the venture capitalists and private equity firms need to invest. widespread public education combined with advocacy against stigma that would facilitate acceptance in the society, is how accurate psychedelic information will be promoted. Business positioning and creating possible growth prospects will be eased when working with healthcare providers and with the pharmaceutical companies and with the mental health organizations.

7. CONCLUSION

Business innovators have the potential promise of psychedelics because they can help them be more creative, have more mental flexibility, and be in better emotional wellness. These substances can impact innovation and problem solving and stress management because a person builds divergent thinking at the same time as strengthening emotional resilience. Questions of what real advantage may come from psychedelics have to be answered by scientists, whether potential advantages outweigh psychological risks, and basic ethical points that include security, dependencies and other common perceptions of these substances. Given this, lawmakers need to evolve their frameworks with such standards that incentivize scientists to create certified application protocols that can be used responsibly. However, it is the research and regulatory reforms that will move together to make psychedelic use valuable in entrepreneurship to become mental health products that boost productivity and creativity.

REFERENCES

[1] Hyman SE. Revolution stalled. Science translational medicine. 2012 Oct 10;4(155):155cm11-.

[2] Pangalos MN, Schechter LE, Hurko O. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nature Reviews Drug Discovery. 2007 Jul;6(7):521-32.

[3] Pankevich DE, Altevogt BM, Dunlop J, Gage FH, Hyman SE. Improving and accelerating drug development for nervous system disorders. Neuron. 2014 Nov 5;84(3):546-53.

[4] Bathje GJ, Majeski E, Kudowor M. Psychedelic integration: An analysis of the concept and its practice. Frontiers in Psychology. 2022 Aug 4;13:824077.

[5] Nichols DE, Walter H. The history of psychedelics in psychiatry. Pharmacopsychiatry. 2021 Jul;54(04):151-66.

[6] Stafford P. Psychedelics encyclopedia. Ronin Publishing; 2013 Feb 18.

[7] Yaden DB, Johnson MW, Griffiths RR, Doss MK, Garcia-Romeu A, Nayak S, Gukasyan N, Mathur BN, Barrett FS. Psychedelics and consciousness: Distinctions, demarcations, and opportunities. International Journal of Neuropsychopharmacology. 2021 Aug 1;24(8):615-23.

[8] Letheby C, Mattu J. Philosophy and classic psychedelics: A review of some emerging themes. Journal of Psychedelic Studies. 2022 Feb 1;5(3):166-75.

[9] Langdon E. J. (1979). Yagé among the Siona: Cultural patterns and visions. In David Browman and Ron Schwarz, (eds.), Spirits, shamans and stars: Perspectives from South America, Mouton_Pub (pp. 63–82).

[10] Langlitz N. (2012). Neuropsychedelia: The revival of hallucinogen research since the decade of the brain. University of California Press.

[11] Larøi F., Luhrmann T. M., Bell V., Christian W. A. Jr., Deshpande S., Fernyhough C., Jenkins J., Woods A. (2014). Culture and hallucinations: Overview and future directions. Schizophrenia bulletin, 40(Suppl_4), S213–S220

[12] Leary T. (1961). Drugs, set & suggestibility. Paper presented at the annual meeting of the American Psychological Association, 6 September 1961

[13] Lifshitz M., van Elk M., Luhrmann T. M. (2019). Absorption and spiritual experience: A review of evidence and potential mechanisms. Consciousness and Cognition, 73, 102760.

[14] Anderson T, Petranker R, Rosenbaum D, Weissman CR, Dinh-Williams LA, Hui K, Hapke E, Farb NA. Microdosing psychedelics: personality, mental health, and creativity differences in microdosers. Psychopharmacology. 2019 Feb 14;236:731-40.

[15] Brown M. F. (1978). From the hero's bones, three aguaruna hallucinogens and their uses. The Nature and Status of Ethnobotany, 67, 119–136.

[16] Carhart-Harris R. L., Kaelen M., Whalley M. G., Bolstridge M., Feilding A., Nutt D. J. (2015). LSD enhances suggestibility in healthy volunteers. Psychopharmacology, 232(4), 785–794

[17] Carhart-Harris R. L., Leech R., Hellyer P. J., Shanahan M., Feilding A., Tagliazucchi E., Chialvo D. R., Nutt D. (2014). The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs. Frontiers in Human Neuroscience, 8, 20.

[18] Carhart-Harris, R. L. Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018). Psychedelics and the essential importance of context. Journal of Psychopharmacology, 32(7), 725–731.

[19] Chaumeil J.-P. (1983). Voir, savoir, pouvoir: Le chamanisme chez les Yagua du nord-est péruvien. Editions de l'Ecole des hautes études en sciences sociales.

[20] Chaumeil J.-P. (2010). Des sons et des esprits-maîtres en Amazonie amérindienne. Ateliers d'anthropologie. Revue éditée par le Laboratoire d'ethnologie et de sociologie comparative, 34.

[21] Corlett P. R., Frith C. D., Fletcher P. C. (2009). From drugs to deprivation: A Bayesian framework for understanding models of psychosis. Psychopharmacology, 206(4), 515–530.

[22] Csordas T. J., Harwood A. (1994). Embodiment and experience: The existential ground of culture and self (Vol. 2). Cambridge University Press.

[23] De Rios M. D., Katz F. (1975). Some relationships between music and hallucinogenic ritual: The "jungle gym" in consciousness. Ethos, 3(1), 64–76.

[24] Déléage P. (2009). Le chant de l'anaconda: L'apprentissage du chamanisme chez les Sharanahua (Amazonie occidentale) (Vol. 8). Société d'ethnologie.

[25] Dobkin de Rios M. (1972). Visionary vine: Hallucinogenic healing in the Peruvian Amazon. Waveland Press, Inc.

[26] Dobkin de Rios M. (1974). Cultural persona in drug-induced altered states of consciousness. Th. Fitzgerald (Hg.) Social and Cultural Identity. Proceedings, 8.

[27] Dupuis D. (2018). L'ayahuasca et son ombre. L'apprentissage de la possession dans un centre chamanique d'Amazonie péruvienne. Journal de la société des américanistes, 104(2), 33–63

[28] Dupuis D. (2019). Apprendre à voir l'invisible. Pédagogie visionnaire et socialisation des hallucinations dans un centre chamanique d'Amazonie péruvienne. Cahiers d'anthropologie sociale, 17(2), 20–42.

[29] Mansour TE. The effect of lysergic acid diethylamide, 5-hydroxytryptamine, and related compounds on the liver fluke, Fasciola hepatica. British Journal of Pharmacology and Chemotherapy. 1957 Dec;12(4):406-9.

[30] Lenz C, Sherwood A, Kargbo R, Hoffmeister D. Taking different roads: l-Tryptophan as the origin of psilocybe natural products. ChemPlusChem. 2021 Jan;86(1):28-35.

[31] Araújo AM, Carvalho F, Bastos MD, Guedes de Pinho P, Carvalho M. The hallucinogenic world of tryptamines: an updated review. Archives of toxicology. 2015 Aug;89:1151-73.

[32] McKenna D, Riba J. New world tryptamine hallucinogens and the neuroscience of ayahuasca. Behavioral Neurobiology of Psychedelic Drugs. 2018:283-311.

[33] Liu C, Jia W, Qian Z, Li T, Hua Z. Identification of five substituted phenethylamine derivatives 5-MAPDB, 5-AEDB, MDMA methylene homolog, 6-Br-MDMA, and 5-APB-NBOMe. Drug testing and analysis. 2017

Feb;9(2):199-207.

[34] King LA. New phenethylamines in Europe. Drug Testing and Analysis. 2014 Jul;6(7-8):808-18.

[35] Dinis-Oliveira RJ, Pereira CL, Da Silva DD. Pharmacokinetic and pharmacodynamic aspects of peyote and mescaline: clinical and forensic repercussions. Current molecular pharmacology. 2019 Aug 1;12(3):184-94.

[36] Nieddu M, Baralla E, Sodano F, Boatto G. Analysis of 2, 5-dimethoxy-amphetamines and 2, 5-dimethoxy-phenethylamines aiming their determination in biological matrices: a review. Forensic Toxicology. 2023 Jan;41(1):1-24.

[37] Glatfelter GC, Pham DN, Walther D, Golen JA, Chadeayne AR, Baumann MH, Manke DR. Synthesis, structural characterization, and pharmacological activity of novel quaternary salts of 4-substituted tryptamines. ACS omega. 2022 Jul 5;7(28):24888-94.

[38] ABRAHAM John, 2010, "Pharmaceuticalization of Society in Context: theoretical, empirical and health dimensions", Sociology, 44, 4: 603-622.

[39] BADINER Allan and Alex GREY, 2015, Zig Zag Zen. Buddhism and Psychedelics, Santa Fe/London, Synergetic Press.

[40] BAGGOTT Matthew J., 2015, "Psychedelics and creativity: a review of the quantitative literature," PeerJ Preprints [https:// doi.org/10.7287/peerj.preprints.1202vl, 10.08.2018].

[41] BARRON Frank, 1963, Creativity and Psychological Health, Princeton, Van Nostrand.

[42] BERG Jos Ten, 1999, "Breakdown or Breakthrough? A History of European Research into Drugs and Creativity," Fourth Quarter, 33-34: 257-276. BIANCARDI Vittorio, 2017, « La recherche sur les microdoses de substances psychédéliques. James Fadiman, Sophie Korbe et les "micro-doses" », Chimères, 91-1: 139-148.

[43] BISBEE Cynthia Carson, Paul BISBEE, Ericka DYCK et al., 2018, Psychedelic Prophets. The Letters of Aldoux Huxley and Humphry Osmond, Montreal & Kingstone, London/Chicago, McGill-Queen's University Press.

[44] CALLARD Felicity and Daniel S. MARGULIES, 2014, "What we talk about when we talk about the default mode network," Frontiers in Human Neurosciences, 619: 1-5. COHEN-COLE Jamie, 2014, The Open Mind: cold war Politics and the sciences of human Nature, Chicago, University of Chicago Press.

[45] COOPER M. R., B. S. MORGAN, P. M. FOLEY, and L. B. KAPLAN, (January-February) 1979, "Changing Employee Values: deepening discontent?", Harvard Business Review: 117-125. COVENEY Catherine, Jonathan GABE and Simon WILLIAMS, 2011, "The sociology of cognitive enhancement: medicalization and beyond," Health Sociology Review, 20, 4: 381-393.

[46] CSIKSZENTMIHALYI Mihaly, 1975, "Play and Intrinsic Rewards," Journal of Humanistic Psychology, 15, 3: 41-73.

[47] DEMING Edwards, 1986, Out of the crisis, Cambridge, MIT Press. DYCK Erika, 2008, Psychedelic Psychiatry. LSD from Clinic to Campus, Baltimore, The Johns Hopkins University Press. EARP Brian, 2018, "Psychedelic moral enhancement," in Michael Hauskeller and Coyne Lewis (eds), Moral Enhancement: critical perspectives, Cambridge, Cambridge University Press [https://www.academia.edu/33771413/Psychedelic_moral_ enhancement, 10.08.18].

[48] ELCOCK Chris, 2015, "The fifth freedom: the politics of psychedelic patriotism," Journal for the Study of Radicalism, 9, 2: 17- 40.

[49] ELSEY James W. B., 2017, "Psychedelic drug use in healthy individuals: a review of benefits, costs, and implications for drug policy," Drug Science, Policy and Law, 3: 1-11.

[50] ERDMANN Martin, 2009, "The Spiritualization of Science, Technology, and Education in a One-World Society," European Journal of Nanomedicine, 2: 31-38

[51] Schlag, A. K., Aday, J., Salam, I., Neill, J. C., & Nutt, D. J. (2022). Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. Journal of Psychopharmacology, 36(3), 258-272.

[52] Siegel, A. N., Meshkat, S., Benitah, K., Lipsitz, O., Gill, H., Lui, L. M., ... & Rosenblat, J. D. (2021). Registered clinical studies investigating psychedelic drugs for psychiatric disorders. Journal of Psychiatric Research, 139, 71-81.

[53] Marks M, Brendel RW, Shachar C, Cohen IG. Essentials of informed consent to psychedelic medicine. JAMA psychiatry. 2024 Jun 1;81(6):611-7.

[54] Edmondson AC. The fearless organization: Creating psychological safety in the workplace for learning, innovation, and growth. John Wiley & Sons; 2018 Nov 20.

[55] Palmier-Claus JE, Dunn G, Lewis SW. Emotional and symptomatic reactivity to stress in individuals at ultra-high risk of developing psychosis. Psychological medicine. 2012 May;42(5):1003-12.

[56] Benfer EA. Health justice: a framework (and call to action) for the elimination of helath inequity and social justice. Am. UL Rev.. 2015;65:275.

[57] Schwarz-Plaschg C. Socio-psychedelic imaginaries: envisioning and building legal psychedelic worlds in the United States. European Journal of Futures Research. 2022 Dec;10(1):10.

[58] Yao Y, Guo D, Lu TS, Liu FL, Huang SH, Diao MQ, Li SX, Zhang XJ, Kosten TR, Shi J, Bao YP. Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis. Psychiatry Research. 2024 Mar 28:115886.

[59] Aday JS, Barnett BS, Grossman D, Murnane KS, Nichols CD, Hendricks PS. Psychedelic commercialization: A wide-spanning overview of the emerging psychedelic industry. Psychedelic Medicine. 2023 Sep 1;1(3):150-65.

[60] Copes H, Copeland H, Vieraitis L, Cherbonneau M, Hendricks P. “Plants Don’t Have a Culture to Appropriate”: Accounting for Accusations of Cultural Appropriation of Peyote Ceremonies. Sociology Compass. 2025 Mar;19(3):e70048.

[61] Andrews CM, Hall W, Humphreys K, Marsden J. Crafting effective regulatory policies for psychedelics: What can be learned from the case of cannabis?. Addiction. 2025 Feb;120(2):201-6.

❖❖❖❖❖